Silvina M Richard, Veronica L Martinez Marignac1. 1. Microscopy Laboratory Applied to Molecular and Cellular Studies, Engineering School, National University of Entre Rios, (3101) Oro Verde, Entre Rios, Argentina.
Abstract
AIM OF STUDY: In the present study, we evaluated the effect of ribavirin and metformin on the sensitivity of oxaliplatin and 5-fluorouracil (5-FU) on colon cancer. MATERIALS AND METHODS: Cell viability of two commercially available colon cancer cell lines (HT29 and HCT116) were analyzed by sulforhodamine B (SRB) assay. RESULTS: A clinically achievable and nontoxic concentration of ribavirin and metformin showed a significant synergistic effect on oxaliplatin in HT29 and HCT116 cell lines. Ribavirin showed a synergistic effect on oxaliplatin in HT29 (R = 2.93, P < 0.001) and HCT116 (R = 1.71, P < 0.001), while only in HT29 metformin synergized with oxaliplatin by 2.66 (± 0.28, P < 0.01). In addition, both cell lines showed significant differences in response to Compound 968, inhibitor of mitochondrial glutaminase activity. CONCLUSION: The data suggested that these cell lines not only turn to metabolic different sustainability process after oxaliplatin treatment but that they also have different basal metabolic requirements of glutamine in vitro which can be exploits in the future for colorectal cancer (CRC) treatment and further studies are required.
AIM OF STUDY: In the present study, we evaluated the effect of ribavirin and metformin on the sensitivity of oxaliplatin and 5-fluorouracil (5-FU) on colon cancer. MATERIALS AND METHODS: Cell viability of two commercially available colon cancer cell lines (HT29 and HCT116) were analyzed by sulforhodamine B (SRB) assay. RESULTS: A clinically achievable and nontoxic concentration of ribavirin and metformin showed a significant synergistic effect on oxaliplatin in HT29 and HCT116 cell lines. Ribavirin showed a synergistic effect on oxaliplatin in HT29 (R = 2.93, P < 0.001) and HCT116 (R = 1.71, P < 0.001), while only in HT29 metformin synergized with oxaliplatin by 2.66 (± 0.28, P < 0.01). In addition, both cell lines showed significant differences in response to Compound 968, inhibitor of mitochondrial glutaminase activity. CONCLUSION: The data suggested that these cell lines not only turn to metabolic different sustainability process after oxaliplatin treatment but that they also have different basal metabolic requirements of glutamine in vitro which can be exploits in the future for colorectal cancer (CRC) treatment and further studies are required.
Authors: Andrea Martisova; Lucia Sommerova; Katarina Kuricova; Jan Podhorec; Borivoj Vojtesek; Katerina Kankova; Roman Hrstka Journal: Oncol Lett Date: 2019-09-04 Impact factor: 2.967
Authors: F Volpin; J Casaos; J Sesen; A Mangraviti; J Choi; N Gorelick; J Frikeche; T Lott; R Felder; S J Scotland; T S K Eisinger-Mathason; H Brem; B Tyler; N Skuli Journal: Oncogene Date: 2016-12-12 Impact factor: 9.867
Authors: Claudio Vernieri; Fabio Galli; Laura Ferrari; Paolo Marchetti; Sara Lonardi; Evaristo Maiello; Rosario V Iaffaioli; Maria G Zampino; Alberto Zaniboni; Sabino De Placido; Maria Banzi; Azzurra Damiani; Daris Ferrari; Gerardo Rosati; Roberto F Labianca; Paolo Bidoli; Giovanni L Frassineti; Mario Nicolini; Lorenzo Pavesi; Maria C Tronconi; Angela Buonadonna; Sabrina Ferrario; Giovanni Lo Re; Vincenzo Adamo; Emiliano Tamburini; Mario Clerico; Paolo Giordani; Francesco Leonardi; Sandro Barni; Andrea Ciarlo; Luigi Cavanna; Stefania Gori; Saverio Cinieri; Marina Faedi; Massimo Aglietta; Maria Antista; Katia F Dotti; Francesca Galli; Maria Di Bartolomeo Journal: Oncologist Date: 2019-01-03
Authors: Mariquit M De Los Reyes; Glenn G Oyong; Vincent Antonio S Ng; Chien-Chang Shen; Consolacion Y Ragasa Journal: Pharmacognosy Res Date: 2018 Jan-Mar
Authors: Betty Tyler; Nicolas Skuli; Joshua Casaos; Sakibul Huq; Tarik Lott; Raphael Felder; John Choi; Noah Gorelick; Michael Peters; Yuanxuan Xia; Russell Maxwell; Tianna Zhao; Chenchen Ji; Thomas Simon; Julie Sesen; Sarah J Scotland; Richard E Kast; Jeffrey Rubens; Eric Raabe; Charles G Eberhart; Eric M Jackson; Henry Brem Journal: Oncotarget Date: 2018-01-03
Authors: Allison S Cohen; Ling Geng; Ping Zhao; Allie Fu; Michael L Schulte; Ramona Graves-Deal; M Kay Washington; Jordan Berlin; Robert J Coffey; H Charles Manning Journal: Transl Oncol Date: 2020-07-08 Impact factor: 4.243